What question did this study set out to answer?

To demonstrate the safe use of neuraxial anesthesia in a patient with severe hemophilia A while utilizing extended half-life factor VIII.

June 20, 2026A&A PracticeOpen Access

Neuraxial Anesthesia in Severe Hemophilia A Using Extended Half-Life Factor VIII (Efanesoctocog Alfa): A Case Report

View Full Paper

Ask AI

Bookmark

Authors

APAby Dixon PynadathIllinois College ABAleyna Grace BrunnerIllinois College

Discussion

Member takes

Implication

Case report shows safe neuraxial anesthesia in a patient with severe hemophilia A using efanesoctocog alfa, indicating effective perioperative management.

Key Points

To demonstrate the safe use of neuraxial anesthesia in a patient with severe hemophilia A while utilizing extended half-life factor VIII.
Individual case report of a 52-year-old man with severe hemophilia A.
Total knee arthroplasty performed under spinal anesthesia with an adductor canal block.
Factor VIII levels sustained using both EHL and standard factor VIII replacement.
The patient experienced no neurologic sequelae.
Successful maintenance of FVIII levels throughout the procedure.
Safe neuraxial anesthesia achieved without complications.

Cite This Study

Pynadath et al. (2026) studied this question.

synapsesocial.com/papers/6a36309edb0793dc1a537b80 https://doi.org/10.1213/xaa.0000000000002236

View Full Paper

Ask AI

Bookmark

Implication

Case report shows safe neuraxial anesthesia in a patient with severe hemophilia A using efanesoctocog alfa, indicating effective perioperative management.

Neuraxial Anesthesia in Severe Hemophilia A Using Extended Half-Life Factor VIII (Efanesoctocog Alfa): A Case Report

Discussion

Member takes

Implication

Key Points

Cite This Study

Neuraxial Anesthesia in Severe Hemophilia A Using Extended Half-Life Factor VIII (Efanesoctocog Alfa): A Case Report

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider